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Abstract We have cloned the genomic DNA ofcalmegin 1(1992) 
J. Biol. Chem. 269, 7744-7749] and analyzed its promoter egion. 
It contained GC-rich sequences and potential binding sites for AP 
2 and Sp 1, but lacked the TATA sequence. The 330 bp 5' flanking 
sequence of calmegin genomic DNA fused with the CAT gene was 
used for the study of promoter activity in transgenic mice. The 
CAT gene activity was detected exclusively in testes, indicating 
that the 330 bp calmegin 5' sequence was sufficient for the testis- 
specific expression. The existence of testicular nuclear factors 
specifically bound to the putative promoter sequence was also 
demonstrated. 
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1. Introduction 
Mammalian spermatogenesis is a complex process including 
the proliferation of spermatogonia, meiosis of spermatocytes 
and drastic morphological changes from spermatid to sperm. 
During the process many male germ cell-specific molecules 
were expressed utilizing the germ cell-specific transcriptional 
systems [2,3]. Recently some of these genes were isolated by 
using germ cell-specific antibodies or identified as related mol- 
ecules of some somatic genes. However, the germ cell-specific 
genes reported so far are not so many. Moreover, the lack of 
male germ cell lines makes it difficult to study the germ cell- 
specific transcriptional regulation. These are the reasons why 
the structure and the regulatory mechanism of male germ cell- 
specific promoters are not well understood yet. 
Calmegin is a Ca 2+ binding protein specifically and abun- 
dantly expressed in meiotic germ cells from pachytene sperma- 
tocytes to spermatids. We have recently molecularly cloned the 
cDNA encoding calmegin using specific monoclonal antibody 
[1,4]. Although the precise function of calmegin is still unclear, 
a high homology to the calreticulin (the major Ca 2+ binding 
protein of ER membrane) as well as to the calnexin (ER mem- 
brane phosphoprotein) [5-7] implied its physiological function 
involving Ca 2+ binding. In fact, we have demonstrated a Ca 2+ 
binding activity of this protein [1]. Furthermore, calmegin 
mRNA was expressed only in the male meiotic germ cells and 
not in other somatic cells [1]. 
From these lines of evidence it is conceivable that some 
cis-acting element in the calmegin promoter region and its 
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trans-acting factors are present in testes for germ cell-specific 
expression. 
In the present study, to examine these possibilities, we have 
isolated the genomic DNA of calmegin gene, and analyzed the 
promoter sequence and transcriptional starting sites. Further- 
more, we produced transgenic mice containing a calmegin-CAT 
fusion gene and analyzed promotor activities in variuous tissues 
of the transgenic mice. Here we showed that the 330-bp cal- 
megin 5' flanking region was sufficient o direct testis-specific 
gene expression and that some testicular nuclear factors bound 
specifically to this promoter sequence. 
2. Materials and methods 
2.1. Molecular cloning and DNA sequencing of the calmegin genomic 
gene 
Liver DNA obtained from 129 mice was digested with endonuclease 
Sau3AI and cloned into the BamHI site of 2 phage EMBL3. About 
3 x 106 recombinant phage plaques were screened with a radio-labeled 
PstI-EeoRI 700-bp 5' region of the calmegin cDNA [1]. Recombinant 
phage DNA was isolated by the standard procedures. Three kbp DNA 
fragment containing a 178-bp calmegin 5' untranslated region at 3' end 
was isolated by digestion with BamHI and subcloned into a pBluescript 
SK+ vector, and sequenced by the dideoxy chain termination method. 
2.2. Plasmid construction and microinjeetion 
The 330-bp SacIlBamHI fragment of the genomic almegin gene 
containing the 178-bp 5' untranslated first exon and 152-bp upstream 
sequence from the transcription i itiation site was cloned into the 
BamHIlSacI restriction sites of pUC O CAT vector [8]. From the 
resulting fusion construct pMegSB-CAT, the DNA fragment was ex- 
cised by PvuIIlSacI digestion and injected into male pronucleus of 
fertilized mouse ggs [27]. Founder transgenic mice were identified by 
Southern blot hybridization using a 32p-labeled CAT probe. 
2.3. CAT enzyme assay 
Various tissues from hemizygous transgenic mice were homogenized 
in 10 mM Tris-HC1, (pH 7.8), heated at 60°C for 10 rain [28], and 
centrifuged at 10000 xg for 5 min. CAT activity of extracted proteins 
(20 mg) in each supernatant was analyzed as described by Gorman et 
al. [29]. 
2.4. Primer extension analysis of the calmegin gene 
A synthetic oligonucleotide complementary to the sequence from 
nucleotide position +93 to +122 of the calmegin cDNA (Fig. 1A) was 
endolabeled with y[32p] ATP by T4 polynucleotide kinase. Primer-RNA 
(30/lg) hybridization and extension reactions were performed as de- 
scribed by Bina-Stein et al. [30]. 
2.5. Gel mobility shift assay 
Nuclear extracts were prepared from testis and liver essentially as 
described by Schreiber et al. [31]. Each nuclear extract (15/.tg) was 
incubated at 4°C for 30 min with 1 Bg non-specific DNA (poly dAdT) 
in a 30/11 volume containing 10% SDS, 12 mM HEPES (pH 7.9), 60 
mM KC1, 0.5 mM EDTA, 0.6 mM DTT, and 0.1/tg of the 5' endola- 
beled calmegin genomic DNA fragment from -152 to +18. The mix- 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)00729-6 
510 D. Watanabe et al./FEBS Letters 368 (1995) 509-512 
tures were loaded on a 4% non-denaturing polyacrylamide g l and 
electrophoresed. The gel was then dried and autoradiographed. 
3. Results 
3.1. Molecular cloning of a 5"-calmegin flanking sequence and its 
primer extension analysis 
From the 2EMBL3 129 male mouse genomic liberary, we 
obtained a 5' flanking region of the calmegin genomic DNA. 
The 330 bp calmegin genomic sequence is shown in Fig. 1A. 
The calmegin 5' flanking sequence contained multiple GC-rich 
(about 73%) sequences, and putative binding sequences for 
transcription factors such as AP2 and SP I. It does not possess 
canonical TATA and CCAAT boxes in the typical locations 
upstream of the transcriptional starting site (Fig. 1A). 
To identify the transcriptional initiation site of calmegin 
gene, we performed a primer extension experiment using a 
oligonucleotide complementary to a 5' untranslated region of 
calmegin cDNA. One strong and three weak signals were de- 
tected only in the testis but not in the liver RNAs (Fig. 2). From 
the RNase mapping analysis, we also detected one major and 
some minor transcriptional starting sites in the same regions 
(data not shown), consistent with the data of the primer exten- 
sion experiment. Although calmegin gene may have several 
minor transcription initiation sites, we concluded that the 
major transcription i itiation site was one strongly identified 
in both primer extention and RNase mapping experiments (see 
'+1' in Fig. 1A). 
3.2. Generation of transgenic mice carrying the 5'flanking 
region of calmegin gene fused with the CAT gene 
The fusion gene used in this experiment is shown in Fig. lB. 
It contained both the 152-bp upstream and 178-bp downstream 
non-coding sequences from the transcriptional initiation site of 
the calmegin gene (Fig. 1B). This segment was fused to the 
SacIlBamHI sites of the vector pUC O CAT [8]. DNA with the 
construct was purified and injected into the single-cell fertilized 
mouse embryos, which were then transferred to the pseu- 
dopregnant foster mothers. The animals containing the trans- 
Sac  I 
-152 GA GCTCCAGAGA GGGACTGACG TTGGAAGGAC 
AP-2 Ava Z 
-120 C G C A T C C ~ G C G  GCCGCTGGGT CCCGAGCGGC GGTTGAGCGG 
-70 GCCGCTTGCG CACTGGGGCT GCCACTGCAT CCTGCATCCT CCGGCGCGGC 
,l sP-i 
-20 CGCTCGCGCA CGCGCAGTTA GCAGTCGCTG C ~ T  GCCGGCGGGA 
+30 TCGCTCTGGG GAGACGCCGG GCACCAAGTA GCGGCCAGTC GGACACCTGA 
+80 GCTGCCGCTG CTGGACACAA GCCCGCAGGA CAGGTGTGTA GACCGCGGGC 
Sam HI 
+130 CGCCTTCCTG CGGCTTGTTC TCTGGGGACC GGGTGAGAAA TCGGATCC 
A 
Sac I &am HI 
I I CAT  I 
1 52 +1 +178 
B 
Fig. 1. A 5' flanking DNA sequence ofthe genomic calmegin gene and 
a construction used for generating transgenic mice. (A) Nucleotides 
were numbered from the first nucleotide of the transcription initiation 
site (+1). Restriction enzyme sites were indicated by underlines. The 
putative binding sites for nuclear factors (AP 2 and SP 1) are indicated 
by boxes. A synthetic oligonucleotide complementary to the underlined 
sequence (from +93 to +122) was used for primer extention analysis. 
(B) The construct injected into fertilized mouse embryos. The construc- 
tion of the calmegin-CAT fusion ge e is described in section 2. 
.,,=2 
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Fig. 2. Primer extension analysis of the calmegin gene. Total RNA (30 
/~g) was hybridized with 5' riP-labeled synthetic oligonucleotides com- 
plementary to the DNA sequence ofthe calmegin cDNA from nucleo- 
tide position +93 to + 122. Primer extension products were synth sized 
and analyzed as described insection 2. Lane 1 -- M13 DNA sequence 
standard to determine each size of primary extended products; lane 
2 = 30/lg of total RNA of liver; lane 3 = 30/lg of total RNA from the 
testis; lane 4 = no RNA. A closed arrowhead indicates the major pri- 
mary extended product and open arrowheads indicate the minor ones. 
gene were identified by Southern blot hybridization of tail 
DNA using the CAT DNA as a probe. Two independent lines 
of transgenic mice TGcal01 and TGcal02 were established. 
Both lines were estimated to carry about 10 copies of the trans- 
gene per genome by Southern blotting analysis as compared 
with known standards (data not shown). 
3.3. Tissue-~pecific expression of the recombinant gene 
Tissues from the adult TGcal01 (hemizygous) mouse were 
homogenized and tested for CAT enzymatic activity by thin 
layer chromatography. As shown in Fig. 3, CAT activity was 
found only in testis, not in any other tissues examined (e.g. liver, 
lung, heart, spleen, kidney, muscle, brain, intestine and ovary). 
The same expression pattern was also observed in another 
transgenic mouse line TGcal02. These results indicated that the 
cis-acting element necessary for testis-specific expression of the 
calmegin gene was present within the 330 bp of the 5' flanking 
sequence. 
3.4. Identification of testicular nuclear factors specifically 
binding to calmegin promoter sequences 
To examine factors binding specifically to the calmegin pro- 
moter egion, a 170-bp calmegin genomic sequence from nucle- 
otide position -152 to +18 was ubjected to a gel shift assay 
using a testis and a liver nuclear extract. Three retarded bands 
were observed only when the testis nuclear extract was used 
(Fig. 4, lane 2). Futhermore, the three bands disappeared in the 
presence of 100-fold excess of the unlabeled fragments, which 
were used as a competitor (Fig. 4, lane 3). No retarded bands 
were observed with the nuclear extract prepared from the liver 
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(Fig. 4, lane 4). These results trongly suggested that the factors 
binding specifically to the calmegln promoter region existed in 
testes. 
4. Discussion 
Calmegin (Meg 1) is a testis-specific protein that was charac- 
terized by a monoclonal antibody TRA 369 [4]. Using the 
antibody, we have recently cloned and characterized the mouse 
calmegin cDNA [1]. It was found that calmegin has high homol- 
ogies to the calnexin and calreticulins. Both of these proteins 
have a Ca 2+ binding ability and were reported to work as a 
molecular chaperone of the membrane receptor proteins [9,10] 
and a transcriptional repressor of the glucocorticoid receptor 
proteins [11,12]. The Ca 2+ binding ability of calmegin was also 
demonstrated by using the Ca 2+ overlay experiment [1]. Al- 
though the precise function is still unclear, the result may indi- 
cate that calmegin has a function similar to that of either cal- 
reticulins or calnexin. 
The transcription of the calmegin gene occurs exclusively in 
testicular germ cells and not in any other somatic tissues. Thus, 
expression of the calmegin gene is highly regulated. Moreover, 
the expression is limited to pachytene spermatocytes and sper- 
matids. These results uggest that calmegin has some important 
roles in meiosis and spermatogenesis. 
Using the calmegin cDNA, we have isolated the calmegin 
genomic DNA. The promoter region of the calmegin gene con- 
tained a number of GC-rich sequences and did not have a 
canonical TATA or CCAAT box in the typical location up- 
stream of the transcriptional starting site (Fig. 1A). The GC- 
rich sequences were also found in some testis-specific genes 
such as mouse proenkephelin and T complex genes [13-15], and 
may have a role in testis-specific gene expression responsible for 
DNA methylation or chromatin conformation [16-18]. It ap- 
pears that calmegin gene has multiple transcriptional initiation 
sites as demonstrated by primer extension (Fig. 2) and RNase 
mapping analyses (data not shown). The presence of multiple 
initiation sites was also reported in other testis-specific genes 
[14,19]. It was also reported that some genes with multiple 
promoters often exhibited evelopmental stage specific expres- 
sion [20]. The presence of the GC-rich sequences and some 
A B 
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Fig. 3. CAT activities in various tissues of the transgenic mice. Twenty 
mg of protein obtained from the transgenic mouse TGcal01 was as- 
sayed as described in section 2. (A) Tissues from the male transgenic 
mouse; (B) tissues from the female transgenic mouse• T, testis; L, liver
K, kidney; S, spleen; B, brain; M, muscle; H, heart; I, intestine and O, 
ovary. CAT activity was found only in the testis of the transgenic 
mouse. 
Fig. 4. Gel shift assay of calmegin promoter sequence. Gel shift assay 
was performed using the 32p-labeled calmegin genome DNA fragment 
(-152 to +18) with a testis or liver nuclear extract (15/.tg) as described 
in section 2. Lane 1 = the probe only; lane 2 = testicular nuclear extract; 
lane 3 = testicular nuclear extract with the 100-fold excess of unlabeled 
same oligonucleotide; lane 4 = liver nuclear extract. Retarded bands 
specific to the testicular nuclear extract were indicated by arrowheads. 
promoters could allow an additional control and greater flexi- 
bility for calmegin gene expression. Flanking sequences of some 
genes at 5' were responsible for testis-specific gene expression 
[21-24]. However, we could not detect any conserved sequences 
within the calmegin 5' flanking sequence. The 330 bp 5' flanking 
sequence of the calmegin gene characterized in the present 
study is very short for testis-specific transcription i compari- 
son with those of the already reported genes. It contained only 
the 152 bp putative promoter sequence upstream of the tran- 
scription initiation site. Therefore, the cis-acting element regu- 
lating testis-specific transcription must exist within this se- 
quence. Some testis-specific genes were controlled by a silencer- 
like element capable of inhibiting the transcription in other 
somatic tissues [25]. However, the calmegin promoter sequence 
seems to be too short to include such a negative lement, indi- 
cating that the calmegin gene is positively regulated by uniden- 
tified cis-acting elements localizing in the 5' flanking sequence. 
In this context, this promoter sequence could he useful for 
characterizing the mechanism of testis-specific gene expression. 
In the present study, using the gel shift assay we have also 
demonstrated that the nuclear factors in the testis pecifically 
bound to the calmegin promoter sequence (Fig. 4). Recently, 
the presense of many cis-acting dements and trans-acting fac- 
tors has been demonstrated and some of the mechanisms of 
tissue-specific or development-specific gene expression were 
characterized. As for the testis, a few reports are available. 
Some testicular nuclear factors that bind to testis-specific gene 
promoters have been identified [24,26]. Although, the DNA 
fragment we used contained potential binding sites for SP 1 and 
AP2, any shift bands were not observed in our experimental 
condition with the liver nuclear extract. However, we were able 
to demonstrate specific binding of testicular extract o the DNA 
512 
fragment. Thus, the testicular nuclear factors identified in our 
experiment specifically bound to the calmegin promoter se- 
quence. The molecular properties of the nuclear factors and 
their binding sequences are not fully characterized yet. How- 
ever, we assume the factors would have some important roles 
in specific gene expressions during male germ cell differentia- 
tion in the testis. Characterzation of these testicular nuclear 
factors and their target sequences i now in progress. 
Further systematic analyses of the calmegin promoter se- 
quence and the nuclear factors identified in the present study 
will bring us a better understanding of the mechanism of testic- 
ular germ cell-specific gene express ion and the development. 
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